IBI343 combined with IBI308
Phase 2Small molecule
IBI343 combined with IBI308 is one of 54 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
58 competitors in Gastroesophageal Junction Adenocarcinoma
#DrugCompanyPhaseTrials
1Eloxatin
TevaPhase 3
Elunate
TakedaApproved
Lenvima
EisaiApproved
Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Beyfortus
BeiGenePhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Taxotere
AAvyxa
Phase 3
Herceptin
OOrganon and Co
Phase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IBI343 combined with IBI308. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHarbin Medical University